KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Retained Earnings: 2018-2024

Historic Retained Earnings for Aurinia Pharmaceuticals (AUPH) over the last 7 years, with Dec 2024 value amounting to -$936.6 million.

  • Aurinia Pharmaceuticals' Retained Earnings rose 8.30% to -$860.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$860.2 million, marking a year-over-year increase of 8.30%. This contributed to the annual value of -$936.6 million for FY2024, which is 0.61% up from last year.
  • According to the latest figures from FY2024, Aurinia Pharmaceuticals' Retained Earnings is -$936.6 million, which was up 0.61% from -$942.3 million recorded in FY2023.
  • Aurinia Pharmaceuticals' 5-year Retained Earnings high stood at -$575.2 million for FY2020, and its period low was -$942.3 million during FY2023.
  • Moreover, its 3-year median value for Retained Earnings was -$936.6 million (2024), whereas its average is -$914.4 million.
  • As far as peak fluctuations go, Aurinia Pharmaceuticals' Retained Earnings tumbled by 31.46% in 2021, and later increased by 0.61% in 2024.
  • Over the past 5 years, Aurinia Pharmaceuticals' Retained Earnings (Yearly) stood at -$575.2 million in 2020, then plummeted by 31.46% to -$756.1 million in 2021, then declined by 14.31% to -$864.3 million in 2022, then decreased by 9.03% to -$942.3 million in 2023, then grew by 0.61% to -$936.6 million in 2024.